Elisa Genuardi
Overview
Explore the profile of Elisa Genuardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ragaini S, Galli A, Genuardi E, Gandossini M, Alessandria B, Civita A, et al.
Blood Adv
. 2025 Jan;
PMID: 39808795
Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell lymphoma (MCL) remains unclear. Here, we report a comprehensive NGS-based analysis...
2.
Brugiapaglia S, Bulfamante S, Curcio C, Arigoni M, Calogero R, Bonello L, et al.
Front Immunol
. 2024 Aug;
15:1427424.
PMID: 39176093
Introduction: Pancreatic Ductal Adenocarcinoma (PDA) is one of the most aggressive malignancies with a 5-year survival rate of 13%. Less than 20% of patients have a resectable tumor at diagnosis...
3.
Clerico M, Ferrero S, Alessandria B, Zaccaria G, Genuardi E, Ragaini S, et al.
Sci Rep
. 2024 Jul;
14(1):16946.
PMID: 39043871
In the frontline high-dose phase 3 FIL-MCL0208 trial (NCT02354313), 8% of enrolled mantle cell lymphoma (MCL) patients could not be randomised to receive lenalidomide (LEN) maintenance vs observation after autologous...
4.
Ziccheddu B, Giannotta C, DAgostino M, Bertuglia G, Saraci E, Oliva S, et al.
Blood Cancer J
. 2024 Jul;
14(1):117.
PMID: 39030183
Targeted immunotherapy combinations, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, have shown promising results in patients with relapsed/refractory multiple myeloma (RRMM), leading to a considerable increase in progression-free survival. However,...
5.
Pulsoni A, Ferrero S, Tosti M, Luminari S, Dondi A, Cavallo F, et al.
Lancet Haematol
. 2024 Jun;
11(7):e499-e509.
PMID: 38937025
Background: The mainstay of treatment for early-stage follicular lymphoma is local radiotherapy, with a possible role for anti-CD20 monoclonal antibody (mAb). We aimed to evaluate the effect of these treatments...
6.
Ziccheddu B, Giannotta C, DAgostino M, Bertuglia G, Saraci E, Oliva S, et al.
medRxiv
. 2023 Dec;
PMID: 38106151
Anti-CD38 antibody therapies have transformed multiple myeloma (MM) treatment. However, a large fraction of patients inevitably relapses. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide,...
7.
Oliva S, Genuardi E, Paris L, DAgostino M, ROGERs J, Rota-Scalabrini D, et al.
EClinicalMedicine
. 2023 Jul;
60:102016.
PMID: 37396800
Background: Limited data are available on the concordance between multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) for minimal residual disease (MRD) detection in a large trial for multiple myeloma...
8.
Ferrero S, Grimaldi D, Arrigoni E, Pironti M, Zaccaria G, Alessandria B, et al.
Blood Adv
. 2023 Apr;
7(14):3764-3774.
PMID: 37058477
In the Fondazione Italiana Linfomi MCL0208 phase 3 trial, lenalidomide maintenance (LEN) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL) improved progression-free survival (PFS) vs observation (OBS)....
9.
Gkoliou G, Agathangelidis A, Karakatsoulis G, Lalayanni C, Papalexandri A, Medina A, et al.
Front Oncol
. 2023 Feb;
13:1123029.
PMID: 36845709
The analysis of the immunogenetic background of multiple myeloma (MM) has proven key to understanding disease ontogeny. However, limited information is available regarding the immunoglobulin (IG) gene repertoire in MM...
10.